Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 4/2021

09.09.2021 | Original Article

Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule

verfasst von: Kanuj Malik, Anand Raja, Lalgudi Subramaniam Ravishankar, Kathiresan Narayanaswamy, Venkatraman Radhakrishnan, Tenali Gnana Sagar

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity.
Literatur
1.
Zurück zum Zitat International Agency for Research on Cancer (IARC) (2014) World Health Organization (WHO) GLOBOCAN 2012: cancer incidence and mortality worldwide in 2012 [Internet]. Lyon, France: International Agency for Research on Cancer International Agency for Research on Cancer (IARC) (2014) World Health Organization (WHO) GLOBOCAN 2012: cancer incidence and mortality worldwide in 2012 [Internet]. Lyon, France: International Agency for Research on Cancer
2.
Zurück zum Zitat Old LJ, Clarke DA, Benacerraf B (1959) Effect of bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 184(Suppl 5):291–292CrossRef Old LJ, Clarke DA, Benacerraf B (1959) Effect of bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 184(Suppl 5):291–292CrossRef
3.
Zurück zum Zitat Saint F, Irani J, Patard J et al (2001) Tolerability of bacillus Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology. 57:883–8CrossRef Saint F, Irani J, Patard J et al (2001) Tolerability of bacillus Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology. 57:883–8CrossRef
4.
Zurück zum Zitat Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180–183CrossRef Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180–183CrossRef
5.
Zurück zum Zitat Malmstrom P, Sylvester R, Crawford D et al. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Gue´rin for non–muscle-invasive bladder cancer. Malmstrom P, Sylvester R, Crawford D et al. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Gue´rin for non–muscle-invasive bladder cancer.
6.
Zurück zum Zitat Sylvester RJ, van der Meijden APM, Lamm DL (2002) Intravesical bacillus Calmette-Gue´rin reduces the risk of progression in patients with superficial bladder cancer: a metaanalysis of the published results of randomized clinical trials. J Urol 168:1964–1970CrossRef Sylvester RJ, van der Meijden APM, Lamm DL (2002) Intravesical bacillus Calmette-Gue´rin reduces the risk of progression in patients with superficial bladder cancer: a metaanalysis of the published results of randomized clinical trials. J Urol 168:1964–1970CrossRef
7.
Zurück zum Zitat Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette – Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 163:1124–1129CrossRef Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette – Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 163:1124–1129CrossRef
8.
Zurück zum Zitat Badalament RA, Herr HW, Wong GY et al (1987) A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 5:441–449CrossRef Badalament RA, Herr HW, Wong GY et al (1987) A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 5:441–449CrossRef
9.
Zurück zum Zitat Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumours. J Urol 162:74–76CrossRef Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumours. J Urol 162:74–76CrossRef
10.
Zurück zum Zitat Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K (1995) Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results Cancer 75:552–559PubMed Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K (1995) Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results Cancer 75:552–559PubMed
11.
Zurück zum Zitat Bohle A, Bock PR (2004) Intravesical bacille-Calmette Guerin versus mitomycin Cin superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63:682–687CrossRef Bohle A, Bock PR (2004) Intravesical bacille-Calmette Guerin versus mitomycin Cin superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63:682–687CrossRef
12.
Zurück zum Zitat Nogueira MJL, Solsona E, Unda M (2000) A multicenter randomized prospective study comparing three intravesical therapies, two with bacillus Calmette-Gue´rin immunotherapy and one with mitomycin C chemotherapy in medium and low risk superficial bladder tumors. Eur Urol 37:447 Nogueira MJL, Solsona E, Unda M (2000) A multicenter randomized prospective study comparing three intravesical therapies, two with bacillus Calmette-Gue´rin immunotherapy and one with mitomycin C chemotherapy in medium and low risk superficial bladder tumors. Eur Urol 37:447
14.
Zurück zum Zitat Hinotsu S, Akaza H, Naito S et al (2011) Maintenance therapy with bacillus Calmette-GuerinConnaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 108:187–95CrossRef Hinotsu S, Akaza H, Naito S et al (2011) Maintenance therapy with bacillus Calmette-GuerinConnaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 108:187–95CrossRef
15.
Zurück zum Zitat Nakai Y, Anai S, Tanaka N et al (2016) Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate and high-risk non-muscle-invasive bladder cancer: results from a randomized trial. Int J Urol 23:854–860CrossRef Nakai Y, Anai S, Tanaka N et al (2016) Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate and high-risk non-muscle-invasive bladder cancer: results from a randomized trial. Int J Urol 23:854–860CrossRef
16.
Zurück zum Zitat Serretta V, Gesolfo CS, Alonge V, Cicero G, Moschini M, Colombo R (2016) Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? Urol Int 96:20–24CrossRef Serretta V, Gesolfo CS, Alonge V, Cicero G, Moschini M, Colombo R (2016) Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? Urol Int 96:20–24CrossRef
17.
Zurück zum Zitat Vijjan V, Mandhani A, Kapoor R et al (2006) A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer. Indian J Urol 22:317–321CrossRef Vijjan V, Mandhani A, Kapoor R et al (2006) A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer. Indian J Urol 22:317–321CrossRef
18.
Zurück zum Zitat Agrawal MS, Agrawal M, Bansal S, Agrawal M, Lavania P, Goyal J (2007) The safety and efficacy of different doses of bacillus Calmette-Guerin in superficial bladder transitional cell carcinoma. Urol 70:1075–1078CrossRef Agrawal MS, Agrawal M, Bansal S, Agrawal M, Lavania P, Goyal J (2007) The safety and efficacy of different doses of bacillus Calmette-Guerin in superficial bladder transitional cell carcinoma. Urol 70:1075–1078CrossRef
19.
Zurück zum Zitat Astram A, Khadijah A, Yuri P et al (2014) Effective dose and adverse effects of maintenance bacillus Calmette-Guerin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial. Acta Med Indones 46:298–307PubMed Astram A, Khadijah A, Yuri P et al (2014) Effective dose and adverse effects of maintenance bacillus Calmette-Guerin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial. Acta Med Indones 46:298–307PubMed
20.
Zurück zum Zitat Ojea A, Nogueira JL, Solsona E et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 2007; 52:1398–406. Ojea A, Nogueira JL, Solsona E et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 2007; 52:1398–406.
21.
Zurück zum Zitat Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS (2017) Efficacy of bacillus Calmette-Guerin strains for treatment of non muscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol 198:503–510CrossRef Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS (2017) Efficacy of bacillus Calmette-Guerin strains for treatment of non muscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol 198:503–510CrossRef
22.
Zurück zum Zitat Secanella-Fandos S, Luquin M, Julian E (2013) Connaught and Russian strains showed the highest direct antitumor effects of different bacillus Calmette-Guerin substrains. J Urol 189:711–718CrossRef Secanella-Fandos S, Luquin M, Julian E (2013) Connaught and Russian strains showed the highest direct antitumor effects of different bacillus Calmette-Guerin substrains. J Urol 189:711–718CrossRef
23.
Zurück zum Zitat Hayashi D, Takii T, Fujiwara N et al (2009) Comparable studies of immunostimulating activities in vitro among mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol Med Microbiol 56:116–128CrossRef Hayashi D, Takii T, Fujiwara N et al (2009) Comparable studies of immunostimulating activities in vitro among mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol Med Microbiol 56:116–128CrossRef
Metadaten
Titel
Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule
verfasst von
Kanuj Malik
Anand Raja
Lalgudi Subramaniam Ravishankar
Kathiresan Narayanaswamy
Venkatraman Radhakrishnan
Tenali Gnana Sagar
Publikationsdatum
09.09.2021
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 4/2021
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-021-01439-w

Weitere Artikel der Ausgabe 4/2021

Indian Journal of Surgical Oncology 4/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.